Qiagen’s (QGEN) Buy Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reaffirmed their buy rating on shares of Qiagen (NYSE:QGEN) in a research report report published on Tuesday, MarketBeat.com reports. They currently have a $54.00 price target on the stock, up from their previous price target of $42.00.

Several other research firms have also issued reports on QGEN. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research report on Thursday, October 17th. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Qiagen currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.15.

Qiagen Trading Down 0.4 %

Shares of QGEN opened at $45.97 on Tuesday. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The firm has a market cap of $10.49 billion, a price-to-earnings ratio of 117.87, a PEG ratio of 3.37 and a beta of 0.35. The firm has a 50 day moving average price of $43.18 and a 200-day moving average price of $43.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17.

Institutional Investors Weigh In On Qiagen

Large investors have recently modified their holdings of the stock. TD Asset Management Inc bought a new stake in Qiagen during the second quarter worth about $2,103,000. Jennison Associates LLC boosted its position in shares of Qiagen by 5.0% in the 3rd quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock worth $65,001,000 after purchasing an additional 68,415 shares in the last quarter. Raymond James & Associates grew its stake in shares of Qiagen by 12.7% in the 2nd quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock worth $22,289,000 after buying an additional 61,008 shares during the last quarter. XTX Topco Ltd increased its position in Qiagen by 129.3% during the 3rd quarter. XTX Topco Ltd now owns 20,192 shares of the company’s stock valued at $920,000 after buying an additional 11,385 shares in the last quarter. Finally, Barings LLC purchased a new position in Qiagen during the second quarter valued at $12,463,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.